Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04309617 · ClinicalTrials.gov registry record
Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy
A clinical trial of Renal Cell Carcinoma, sponsored by Pfizer.
- Completed
- Registry status
- 618
- Enrollment target
- 1
- Study location
NCT04309617: Completed study of Renal Cell Carcinoma, sponsored by Pfizer.
NCT04309617 is a study of Renal Cell Carcinoma that has completed, run by Pfizer. The registered enrollment target is 618 participants, above the 238-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (160% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04309617, a study of Renal Cell Carcinoma, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 618 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims at estimating the proportion of patients diagnosed with locoregional renal cell carcinoma who are at high risk for recurrence following nephrectomy, describe referral patterns, and characterize treatment in this population. Outcomes including estimation of the incidence of recurrence and disease-free interval following nephrectomy will be reported overall and among the subgroup off patients receiving adjuvant systemic therapy with sunitinib following nephrectomy.
Primary Outcome
Follow- up time (in years) was duration between index date to the last entry in the medical record, death, or disease recurrence. The date of nephrectomy was considered as index date.
Conditions Studied
Interventions
- PROCEDURE nephrectomy
Study Locations (1)
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 618 participants |
| Start Date | 2019-07-31 |
| Est. Completion | 2020-04-28 |
What the finished NCT04309617 record still lists
NCT04309617 is an observational study that tracks outcomes without assigning an intervention. The registered 618 participants enrollment target is mid-sized for trials with a published cap, above the 238-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (160% higher).
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which nephrectomy is the first listed.
NCT04309617 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT04309617 about?
NCT04309617 is a clinical study titled "Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy". This study aims at estimating the proportion of patients diagnosed with locoregional renal cell carcinoma who are at high risk for recurrence following nephrectomy, describe referral patterns, and characterize treatment in this population. Outcomes including estimation of the incidence of recurrence...
What is the current status of trial NCT04309617?
This trial is currently completed. The enrollment target is 618 participants. The study started on 2019-07-31. Estimated completion is 2020-04-28.
What conditions does trial NCT04309617 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
What interventions are being tested in trial NCT04309617?
The interventions under investigation include: nephrectomy (PROCEDURE).
Who is sponsoring clinical trial NCT04309617?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04309617 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04309617's enrollment target sits among peer trials
618 12th of 121 higher than 110 of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
PET/MR for Characterization of Renal Masses (RMs)
RECRUITING
-
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
RECRUITING
-
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05672927 · 618 participants · Phase 4
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
- NCT06220721 · 618 participants · NA
Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia
- NCT02610179 · 617 participants · NA
Strawberry Candy Twists as an Alternative Screen for Gestational Diabetes: A Prospective Trial
- NCT02282969 · 620 participants
PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI